Examining the effect of SGLT2 inhibitors on the time-to-first recurrence of AF after ablation or cardioversion may be a more pragmatic approach given the increased likelihood of AF recurrence in this patient population. The gene discussed is SLC5A2; the disease is atrial fibrillation.